Remarkably, the initial clinical trials, and now the routine clinical application, of PD-1 and CTLA-4 immune checkpoint therapies for ccRCC treatment were never based on clear pre-clinical evidence that was directly related to this tumour entity, due to the absence of appropriate mouse models. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.